LENZ Q1 Revenue Grows Modestly; Prescriptions Double but Fall Short of Bullish Trigger

What happened

LENZ Therapeutics reported Q1 2026 total revenue of $1.9M, including $1.7M in VIZZ product sales, with approximately 46,000 paid prescriptions filled and over 10,000 prescribing eye care professionals. This represents a modest step up from the Q4 2025 baseline of ~$1.6M net revenue and 20,000 prescriptions, but falls short of the report's bullish case of $4M revenue and 50,000 prescriptions needed to confirm accelerating demand. The DTC campaign launched mid-January had a partial quarter impact, and the sales force expansion is on track for full deployment by end of Q2. Early repeat prescribing behavior remains an important metric, but Q1 data does not yet demonstrate the fixed-cost leverage needed to absorb the sales force and marketing spend. The cash position remains strong, but the ramp remains linear rather than exponential, keeping the base-case scenario intact while the bullish scenario remains unconfirmed.

Implication

If Q2 shows further acceleration toward $3-5M quarterly revenue, the base case becomes more probable and the stock could re-rate toward $14. Failure to build on Q1 momentum would increase dilution risk and support the $7 bear case.

Thesis delta

The Q1 revenue of $1.7M and 46k prescriptions are a marginal beat over Q4 but well below the $4M/50k threshold set for an upward thesis revision. DTC impact was partial, so Q2 becomes the critical proof point. The thesis remains a 'show me' story, with the base case still most likely but the bull case requiring a sharper inflection than seen here.